Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine and Low-dose Naltrexone in Hospitalized COVID-19
NCT04756128Phase 2Completed
- Sponsor
- HealthPartners Institute
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of colchicine, naltrexone in coronavirus disease 2019 (COVID-19), sponsored by HealthPartners Institute. Started Jan 2021; status: completed.
02
Drugs
colchicinenaltrexone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04756128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756128.